Tasly Pharmaceutical (SHA:600535), a unit of China Resources Pharmaceutical (HKG:3320), posted net profit attributable to shareholders of 1.11 billion yuan for 2025, up 15.7% from 955.6 million yuan a year earlier, according to a Feb. 6 Hong Kong bourse filing.
Basic earnings per share came in at 0.74 yuan from 0.64 yuan in the prior year.
Operating revenue slipped 3% to 8.24 billion yuan from 8.50 billion yuan, the filing showed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.